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Abstract The amino acid sequences of the receptors for various 
prostaglandins, thromboxane and lipoxin, which belong to the 
rhodopsin family, were aligned, and a phylogenetic tree was con- 
structed to infer the evolutionary history of the arachidonic acid 
cascade. The obtained tree suggested that the origin of the cy- 
clooxygenase pathway was different from that of the iipoxyge- 
nase pathway. The receptors involved in the cyclooxygenase path- 
way constructed an independent cluster, but the lipoxin A 4 recep- 
tor, which is involved in the lipoxygenase pathway, belonged to 
the cluster of peptide receptors. The primitive form of the cy- 
clooxygenase pathway had been a signal transductiuon system 
composed of prostaglandin E 2 and its receptor associated with 
cAMP metabolism. 
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1. Introduction 
A wide variety of bioactive compounds, which include PGs, 
TXs, leukotrienes and LXs are synthesized from arachidonic 
acid, The bioactive compounds are collectively termed eicosa- 
noids and the metabolic pathway to produce such compounds 
is called the arachidonic acid cascade (for reviews see [1-3]). 
The arachidonic acid cascade is divided into four pathways, i.e. 
the cyclooxygenase pathway, lipoxygenase pathway, cyto- 
chrome P-450 pathway and autooxygenation pathway. PGs 
and TXs are synthesized in the cyclooxygenase pathway. On 
the other hand, leukotrienes and LXs are synthesized in the 
lipoxygenase pathway. The physiological ctions of the eicosa- 
noids are mediated through the corresponding receptors. 
Approaches with recombinant DNA techniques have re- 
vealed various aspects of the receptors for eicosanoids at a 
molecular level. The cDNAs and/or genes of TXA receptors 
from human [4,5], mouse [6] and rat [7] have been cloned and 
sequenced. The nucleotide sequences of cDNAs of receptors 
for PGs have also been determined, and assigned to four 
groups, PGD receptor[8], PGE receptor [9-19], PGF receptor 
[20 22], and PGI receptor [23 25]. The PGE receptors have 
*Corresponding author. Fax: (81) (948) 29 7801. 
been pharmacologically c assified into four subtypes, EP1, EP2, 
EP3 and EP4, based on their agonist/antagonist specificity and 
signal transduction [26]. EP~ couples to PI turnover and cal- 
cium mobilization, EP2 and EP 4 to stimulation of adenylate 
cyclase and EP 3 to inhibition of adenylate cyclase. Four groups 
of PGE receptors encoded by different genes have been cloned. 
Among them, the receptor originally cloned by Watabe et al. 
[10] and that by Sugimoto et al. [12] correspond to the pharma- 
cologically-defined EP~ and EP 3 receptors, respectively. The 
other two species of cloned PGE receptors couple positively to 
adenylate cyclase and have been reported to be EP 2 subtype. 
They are the one cloned originally by Honda et al. [9] and 
another ecently cloned by Regan et al. [19]. While both recep- 
tors are sensitive to some of the EP 2 agonists uch as 11-deoxy 
PGE1, the former is insensitive to butaprost, a typical EP 2 
agonist. In addition, a recent study in our laboratories has 
revealed that it is sensitive to an EP4 antagonist, AH23848, 
indicating that it is EP4 and not EP2**. We, therefore, call the 
'EP2' receptor originally cloned by Honda et al. [9] EP4, and 
that by Regan et al. [10] EP2, in the present study. The EP3 
subtype has multiple isoforms generated by alternative splicing 
[13,15,16,27]. On the other hand, the receptor for LXA, which 
is involved in the lipoxygenase pathway, has been reported to 
be related to the formyl peptide receptor [28]. The receptors for 
PGs, TXA and LXA show similarity in amino acid sequence 
to the members of the rhodopsin family. The rhodopsin family 
includes not only the photoreceptors or rhodopsins but also the 
receptors for peptide hormones, neurotransmitters and 
odorant substances. The members of the family have seven 
membrane-spanning re ions in their amino acid sequences and 
are coupled with the corresponding G-proteins for signal 
transduction, which is also the case with the receptors for 
eicosanoids. 
Computer-assisted sequence comparison is a popular and 
practical method to investigate molecular evolution. As de- 
scribed above, the sequence data of the receptors involved in 
the cyclooxygenase pathway and lipoxygenase pathway have 
been accumulated, which are useful to infer not only the evolu- 
tionary relationships among the receptors but also the evolu- 
tionary history of the arachidonic acid cascade. For the inves- 
tigation of the evolutionary aspects, the amino acid sequences 
of the receptors for PGs, TXA and LXA were aligned and a 
phylogenetic tree was constructed. 
**Negishi, M., Narumiya, S. and Ichikawa, A., unpublished 
observation. 2. Materials and methods 
Abbreviations: TX, thromboxane; PG, prostaglandin; LX, lipoxin; 
TXA, thromboxane A2; PGD, prostaglandin D2; PGE, prostaglandin 
E2; PGF, prostaglandin F2~; PGI, prostacyclin; LXA, lipoxin A4; PAF, 
platelet-activating factor. 
2.1. Multiple alignment 
Twenty receptors for various eicosanoids, together with ten peptide 
receptors and two PAF receptors, were aligned by a computer program 
with the tree-based algorithm [29]. The McLachlan's core matrix [30] 
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was used for the alignment. Highly diverged regions were found in the 
N- and C-terminal regions and the extra- and intracellular domains of 
the receptors, where alignment was neither eliable nor suitable for 
phylogenetic analysis. Therefore, the diverged regions were excluded 
from the alignment. The excluded C-terminal regions of EP3 subtypes 
contained the amino acid sequences generated by alternative splicing. 
The remaining regions were modified by visual inspection to increase 
similarity. 
2.2. Construction of phylogenetic tree 
The genetic distance for every pair of the aligned sequences was 
calculated as the sequence difference with Poisson correction [31]. The 
sites containing aps were excluded from the calculation. Then, a phy- 
logenetic tree was constructed by the neighbor-joining method [32] 
using the genetic distances. Statistical significance for obtained tree 
topology was evaluated by bootstrap analysis [33,34] with one thousand 
iterations of bootstrap resampling and tree reconstruction. 
3. Results and discussion 
The amino acid sequences of the nineteen receptors for PGs 
and TXA were available. The reports on the sequences told that 
the receptors how higher sequence similarity to one another 
than to the other members of the rhodopsin family, which 
suggests that they construct a cluster in the phylogenetic tree 
of rhodopsin family. Contarary to that, the LXA receptor, 
which is related to the formyl peptide receptor [28], showed 
close resemblance to the other peptide receptors rather than to 
the receptors for PGs and TXA. PAF is not an eicosanoid, but 
it is another kind of lipid-derived mediator. PAF receptor also 
belongs to the rhodopsin family [35 38]. To investigate the 
evolutionary elationships within the receptors, the amino acid 
sequences of the receptors including ten peptide receptors were 
aligned (see Fig. 1). A phylogenetic tree of the receptors was 
constructed according to the alignment. 
The tree was divided into two clusters. One of them consisted 
of the receptors for PGs and TXA. Another cluster consisted 
of peptide receptors, which also included PAF receptors and 
LXA receptor. The root of the tree was putatively introduced 
to the midpoint of the branch connecting the two clusters. The 
root node of each cluster ((a) and (b) in Fig. 2) was identified 
using another cluster as an outgroup. Regan et al, [19] previ- 
ously investigated the phylogenetic tree of the PG and TXA 
receptors derived only from human. The topology of the former 
cluster in our tree was consistent with that of Regan et al., 
although the receptors of PGD and PGI were not included in 
their tree, both of which were present in this cluster. Further- 
more, we included in our analysis the LXA receptor and recep- 
tors for PGs and TXA from mammals other than human to 
infer evolution of the receptors in the lipoxygenase pathway 
and to discuss the node for mammalian divergence. 
The root point of the former cluster was identified as node 
(a) in Fig. 2, where the cluster of the receptors was divided into 
two subclusters. One of them included the receptors for PGI, 
PGD and PGE (EP2 and 4 subtypes). The subcluster is here 
referred to as CL-1. On the other hand, another subcluster was 
further divided into two subclusters, CL-2 and CL-3. It is 
known that the signal transduction through the receptors in the 
CL-1 is associated with an increase in intracellular cAME CL-1 
is further divided into two subclsuters. One of them consisted 
of EP4, and another of EP2, PGD and PGI receptors. CL-2 
consisted of the receptors for TXA, PGF and PGE (EPt sub- 
type), which mediate the signal transduction through an in- 
crease in inositol triphosphate. CL-3 was composed of the PGE 
receptors (EP 3 subtype). The signal transduction through EP3 
subtype is associated with a decrease in cAMP, although an 
isoform of EP3 subtype generated by alternative splicing is 
coupled to both stimulation and inhibiton of adenylate cyclase 
and stimulaton of PI turnover [13,27]. 
All the subclusters included PGE receptors although the sub- 
types in the subclusters were different from each other. The 
evolutionary position of PGE receptors in the tree suggested 
that the cyclooxygenase pathway may have been initiated as a 
system composed of PGE and its receptor. Furthermore, it is 
known that the activation of the members of CL-1 and CL-3 
are associated with the cAMP metabolisms. So, the primitive 
PGE receptor may have mediated signal transduction through 
cAMP metabolisms a Regan et al. recently suggested in their 
paper [19]. The node (a) was considered to correspond with a 
gene duplication which may have elaborated the primitive PGE 
receptor to form two functionally different receptors, that is, 
a PGE receptor associated with an increase of cAMP and that 
with a decrease of cAMP. The former was subjected to further 
gene duplication to generate EP 2 and EP 4 subtypes. Then, PGI 
and PGD receptors diverged from the EP 2 subtype. The tree 
suggested that both the functional divergence between EP 4 and 
EP2 and that between PGI and PGD receptors occurred before 
mammalian divergence. The latter was an ancestral receptor for 
EP3 subtype, from which ancestral receptor for EP1 subtype 
had diverged by gene duplication at the node (c). The ancestral 
EP~ subtype had been able to mediate signal transduction 
through inositol triphosphate instead of cAME The ancestral 
EP 1 receptor had further diverged by gene duplications toform 
the receptors for PGF and TXA. On the other hand, the ances- 
tral EP 3 subtype has acquired the mechanism of alternative 
splicing to show several functions without gene duplication. 
Considering that the EP3 subtypes from mouse, rat and rabbit 
have multiple isoforms, the subtype may have been subjected 
to alternative splicing before mammalian divergence. In addi- 
tion, the tree suggested that all the variety of the receptors for 
PGs and TXA have been present before mammalian diver- 
gence, that is, cyclooxygenase pathway may have been estab- 
lished before mammalian divergence. 
....> 
Fig. 1. A multiple alignment ofreceptors for PGs, TXA, LXA, PAF and peptides. The integer in parentheses of each sequence indicates the position 
of the neighboring residue in the primary structure. The abbreviated name of each sequence is shown at the left side to the alignment. MPGI and 
HPGI; mouse [25] and human [23] PGI reeptors, MPGD; mouse PGD receptor [8], HEP2; human PGE receptor (EP 2 subtype) [19], HEP4, MEP4, 
and REP4, human [17], mouse [9] and rat [18] PGE receptors (EP4 subtype), MTXA, RTXA and HTXA; mouse [6], rat [7], human [4] TXA receptors, 
BPGF, MPGF, RPGF; bovine [21], mouse [20] and rat [22] PGF receptors, HEP1 and MEP1; human [11] and mouse [10] PGE receptors (EP1 subtype), 
I-IEP3, RBEP3, MEP3 and RTEP3; human [14], rabbit [16], mouse [12] and rat [15] PGE receptors (EP3 subtype), HSBP; human substance P receptor 
[39], HNMK; human euromedin K receptor [40], HNPY; human europeptide Y receptor [41], HGRP; human gastrin-releasing peptide receptor 
[42], HNMB; human euromedin B receptor [42], HET1; human endothelin-1 receptor [43], GPAF and HPAF; guinea-pig [35] and human [36] PAF 
receptors, HC5A; human C5A anaphylatoxin chemotactic receptor [44], HIL8; human high affinity interleukin-8 receptor A [45], HLPX; human LXA 
receptor [46], HBRB2;human B2 bradykinin receptor [47], HAG2; human type-1 angiotensin-II receptor [48]. '-' indicates gap. 

































50) S TL  - MFVA - GWGNGLALGI  LG 
20) S TL  - MFVA - GVVGNGLALGI  LS  
21) MGAVL FGA - G LLGNL LALVL  LA  
27 ) ISSVMFSA-GVLGNL IALALLA 
23) I PAVMFI  F - GVVGNLVAIVVLC 
48 ) IPAVMFIF -GVVGNLVAIVVLC 
23 ) IPAVMFIF -GVVGNLVAIWLC 
30 ) FAA-  SFCALGLGSNLLALSVLA 
30) FAA - S FCALGLGSNLLALSVLA 
30) FAA" S FCVVGLASNL I2tLSVLA 
32) FSI  - I FMTVGILSNS LA IA I  LM 
32) FSI  - I FMTVGI  LSNS LA IA I  LM 
32) FS I  - I FMTVGIVSNS LA IA I  LM 
38 ) LP I  - FSMTLGAVSNLLALALLA 
40) L PI - FSMTLGAVSNVLALALLA 
31) F PI TMLLT  - G FVGNALAM - LLV  
50) F PI TML I  T - G FVGNALAM - LLV  
31) FP I  TMMVT-  G F V G ~  - LLV  
31) F P I T55MVT - G FVGN~J~AM - LLV  
39) YTV - IVV  - TSVVGNVVVMWI  I L 
91 ) YGV-WA-VAVT~GNLIV IWI IL  
47 ) YGA-V I I - LGVSGN-LAL I I I I  
47) YGV- I I L -  IGL IGNITL IK IFC  
50) YLL -  I IT  - VGL I~NIMLVKI  FI 
86) I SC  TI FI  - VGMVGNATLLR I  I Y 
22) YS  I - I FV- LG I  IANGYVLWVFA 
22) YS I - I FV -LGVIANGYVLWVFA 
44 ) FAV - VFL  - VGVLGNALVVWVTA 
46) YAL-VFL -  LSLLGNSLVMLVIL  
33 ) LGV-  TFV-  LGVLGNGLVIWVAG 
36 ) FLWVLFV-  LATLENI  FVLSVFC 
35) YS  I - I FV- VGI  FGNS LVV lV IY  
81) VLVTGLAVTDLLGTC FLS  PA  - VFVAYA 
51) VLVTGLAATDL I~TS FLS  PA  - VFVAYA 
62) VLVCGLTVTDLLGKCL I  S PM - VLAAYA 
69) VLVTELVFTDLLGTCL I  S PV  - VLASYA 
56) TLVCGLAVTDLLGTLLVS PV - T IATYM 
81) TLVCGLAVTDLLGTLLVS PV  - T IATYM 
56) TLVCGLAVTDLLGTLLVS PV  - T IATYM 
64) ALL  CG LVLTD FLG LLVTGAI  - VAS QHA 
64) ALL  CG LVLTD F I~ LLVTGAV - VAS QHA 
65) T FLCGLVLTD FLGLLVTGTI  - VVSQHA 
68 ) LLASALVITDFFGHL INGTIAVFV-YA 
68 ) LLASGLVITDFFGHL INGGIAVFV-YA 
68) LLASGLVI  TDFFGHL INGGIAVFV - YA  
75) LFVAS LLATDLAGHVl  PGAL  - VLRLYT  
77 ) LFVASLLA IDLAGHVlPGAL-VLRLYT  
67 ) LC IGWLALTDLVGQLLTTPV-V IVVYL  
86) LC  I GWLALTDLVGQLLTS PV  - V I  LVYL  
67 ) LC IGWLALTDLVGQLLTSPV-V ILVYL  
67 ) LC IGWLALTDLVGQLLTSPV-V ILVYL  
69 ) YFL~AEASMAAF-NTVVNFT-YA 
121) YFLVNLAFSDASMAAF - NTLVNF I  - YA  
77 ) I L IVNLSFSDLLVAIMCLPF-TFV-YT  
77 ) LF ISSLALGDLLLL ITCAPV-DAS-RY  
80) I FI SNLAAGDLLLLLTCVPVDASR - YF  
117) AL I  AS  LALGDLI  YVV I  DLP I  - NVF  - KL  
54) I FMVNLTVADLLFL I  T - LPLWI  VY  - YS  
54 ) I FMVNLTMADMLFL I  T - LPLWIVY-  YQ 
73) I WFLNLAVADFLS CLA - LP I  LFTS  - IV  
76) VYLLNLALADLLFALT  - LP I  WAAS - KV  
62 ) ICYLNLALADFSFTAT-  LPFL IVS-  MA 
67) IYLGNLAAADLILACG-LPFWAIT -  IS 
65) VFLLNLALADLC FLLT  - LPLWAVY - TA  
( 121 ) LCDTFAFAMTFFGLASTL I  LFAMAVERCLALSHPYLY  
( 91 ) LCDAFAFAMTFFGLASMLILPAMAVERCLALSHPYLY  
(i 03 ) LCETFAFLM~FFGLASTLQLLAMAVECWLSLGHPFFY  
(108) ACTYFAFAMTFFSLATMLML FAMALERYLS  I GAPLLL  
( 91) LCEYSTF ILLFFSLSGLS I ICA~VERYLA. INHAYFY  
(116) LCDYS TFI  LLFFGLSGLS I I CAMS I ERYLA INHAYFY  
( 91) LCDYSTF ILLFFGLS@LSI ICAMSIERYLA INHAYFY  
(103) LCYFMGVAMVFFGLCPLLLGAAMASERFVGITRPFSR 
(103) LCH FMGAAMVFFGLC PLLLGAAMAAERFVGI  TRP  FS R 
( 104 ) LCRFMGVVMI  FFGLSPLLLGAAMASERYLGITRPPSR 
(107) LCS IFGICMVFSGLCPLFLGSLMAIERCIGVTKP IFH 
(107) LCS IFGISMVFSGLCPLFLGSAMAIERCIGVTNPIFH 
(107) LCSVFGISMVFSGLCPLFLGSTMAIERCIGVTNPLFH 
(109) ACHFLGGCMVFFGLC PLL IX~CGMAVERCVGVTRPLLH 
(Iii) ACH FLGGCMVFFGLC PLLLGCGMAVERCVGVTQPL I  H 
( 106 ) LCTFFGLTMTVFGLSSLF IASAMAVEP31LAIRAPHWY 
(125) LCT  FFGLTMTVFGLS SL  F IASAMAVERALAI  RAPHWY 
(106) LCT  FFGLTMTVFGI~g SLLVASAMAVERALAI  RAPHWY 
(106) LCT  FFGLTMTVFGLS S L LVASAIMAVE RALA 7 RA~HWY 
(104) YCK FHNFFP IAAVFAS I YSMTAVAFDRYM3t I  HPLQ P 
(156) YCRFQNFFP I  TAVFAS I YSMTAIAVDRYMAI  I DPLKP  
(112) MCKLI~PFVQCVS I TVS  I FSLVL  IAVER/~QLI INPRGW 
(112) GCKL I  PF I  QLTSVGVSVFTLTALSADRYKAIVRPMD I 
(115) GCKL I  PVI  QLTSVGVSVFTLTALSADRYRAIVNPMDM 
(157) LCKL  F P FLQKS S VG I TVLNL  CA I~ VDRYRAVA~cWS RV 
( 89 ) ~GCLFF INTYCSVAF IX]V ITYNRFQAVKYP IKT  
( 89) LCNVAC-CLFF INTYCSVAFLGVITYNRFQAVTRP IKT  
(108) ACS I LPSL  I LLNMYAS I LLLAT I  SADRFLLVFKP  IWC 
(109) LCK-VVS LL  KEVN FYS GI  LLLAC I SVDRYLAI  VHATRT 
( 97 ) LCKL IH IVVDINLFGSVFL IGF IALDRCICVLHPVWA 
(102) LCRVVNAI  I SMNLYS SI  CFLMLVS I DRYLALVKTM - S 
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(168) FALPS  IYAFCCLFCS LPLLGLGEH (198) 
(138) LAL  PAI  YAFCIrLFCALp LLG LG QH (168) 
(150) LVAPVVAAFC LAFCALP  FAG FG KF  (180) 
(155) GVLPVIYAVS LLFCS LPLLDYGQy (185) 
(138) LTL  FAV~fASNArL F CALPNMGLG S S (168) 
(163) L TL  FAI  yASN~/L F ~NMG LGRS (193) 
(138) L TL  FAVYASNVLF  CALPNMGLG RS (168) 
(149) ATVGLVWVAAGALG - LP  LLG LG Ry  (179) 
(149) ATVG LVWVGAGTLGLLPLLG LG Ry  (179) 
(151) ATVGLVWAAALALGL LP  LLGVG Ry  (181) 
(154) MMLSGVC F FAVFVALLP  I LG  HRDY (184) 
(154) M I LS  GVCMFAVFVAVLP  I LGHRDY (184) 
(154) MI  LSGVCMFAVFVALLP  I LGHRDY (184) 
(156) LAI2h~VAAVALAV~J~ L P LARVG Ry  (186) 
(158) LALAVLAAMALAVAL LPLVHVGRY (188) 
(153) AVLLGVWLAVLAFAL  LPVLGVG QY (183) 
(172) AVLLGVWLAVLAFAL  LPVLGVGQY (202) 
( 152 ) PVLLGVWLSVLAFALLPVLGVGRY ( 182 ) 
(152) PVL  LGVWL SVLAFAL  LPVLGVG Ry  (182) 
(149) VV I  CV IWVLALL  - LAFPQGYYS TT  (178) 
(201) I V I  GS IWI  LAFL  - LAFPQCLYS KT  (230) 
(157) VGIAV IWVLAVA-SSLPFL IYQVM (196) 
(160) KAA - F IWI  I SML  - LA I  PEAVFSDL (194) 
(163) KAM - G IWVVSVL  - LAVPEAVFS EV (195) 
(205) E IV  ~ S IWI LS FI - LAI  PEA l  FVMV (236) 
(136) ALS  LVIWV/LI VA  - ~A - S YFLVMDS (171) 
(136) S LSLV IWVAIVG-  AA - SYFL I  LDS (171) 
(155) I ACAVAWGLALL  - LT  I PS FLYRVV (186) 
(155) FVC LGCWGLS ~ - LS LP  FFL  FRQA (185) 
(145) V IV  - G PWI LALV - LTLPVFL  FLTT  (174) 
(149) LYS  LV IWGCTLL  - LS  S PMLVFRTM (182) 
(147) VTC I I IWLLAGL-  AS  LPAI  IHRNV (178) 
(268) L I - LL  - ALMTVI  MAVCS LPL  - M I  RGFTQAI  
(238) L I - LL  - ALMTVVMAVCS LPL  - T I  RC FTQAV 
(263) FV  - LL  - ALMq"4L FTMCS LPL  - I YRAYYGAF 
(263) L I  - LL -A IMT ITFAVCS LPF  - T I  FAYMNET 
(271 ) V l  - LL IATS  - LVVL ICS IPL -VVRVFVNQL 
(299) V I  - LL IATS  - LVVL I  CS  I PL- VVRVF INQL 
(274) V I  - LL IATS-  LVVL I  CS I PL- VVRVF INQL 
(241) MVQLV -GI M - WATVCWMPL - LVF  IMQTLL  
(241) MVQLV - GIM-  VVATVCWMPL - LVF I  LQTLL  
(244) MAQLL  - GI  M - VVASVCWLPL  - LVF IAQTVL  
(248) V IQLL -  GI M - CVSCI  CWSPF-  L ~  IGM 
(248) I IQLL  -A IM - CVSCVCWSPF-  LVTM3tNIAI 
(248) V I  QLL  -/LI M - CVS CVCWS PF  - LVTMANIA I  
(296) VGQLV - GI  M - VVSCI  CWSPM-  LVLVA-  LAV 
(299) VGQLV-  G IM-  VVSCI  CWSPL-  LVLVV - LA I  
(258) A I  QLM- G IM-  CVLSVCWSPL  - L IMMLKMI  F 
(277) A I  QLM-  G IM-  CVLSVCWSPL  - L IMMLKMI  F 
(257) A IQLM - GI  M - CVLSVCWSPL-  LIMS~LKMI F 
(257) A IQLM - G IM-  CVLSVCWSPL-  LIM~ILKMI F 
(246) VVKMMIVVV-  CTFA I  CWLPFHI  FFLLP  - y I  
(296) V~/KMMI IVV  - MT  FAI CWLPYHI  yF  i LT  - A I  
(261) I N I  MLLS  I V - VAFAVCWLPLT I  FNTVF  - DW 
(262) LAKTVLVFV - GL  FAFCWLPNHVI  YLYRSYH 
(263) LAK IVLVFV-GCF IFCWFPNHIL Iq4YR-SF  
(303) VAKTVFCLV - V I  FALCW FPLHLSRI  LKKTV 
(230) A/LWM~CTVL - AVFV l  C FVPHHMVQ - LPWTL 
(230) ALWMVCq~/L - AVF I  I CFVPHHVVQ - L PWTL 
(240) TLKVVVAW - AS  FFI  FWLPYQVTGI  MM - S - 
(240) ~MRVI  FAVV - L I  FLLCWLPYNLg-LLAD - TL  
(239) PLRVLTAVV - AS  FFI  CW FPFQLVALLG - TV  
(241) ATVLVLVVL  - LLF I  I CWLPFQI  STFLD-  TL  
(238) I FK I  IMAIV-  LFFFFSWI  PHQI  FTFLD-  VL  
SWC - FI RM - R 
SWC-  FLRM - R 
TWC- FI QMIH 
TWC-  FI RHGR 
TWC-  F IDWTT 
TWC - F IDWTT 
TWC- FI DWTT 
SWC- FLTLGT 
SWC-  FLTLGA 
SWC-  FLTLGA 
TWC-  FYKTDE 
TWC- FYNTEH 
TWC-  FYNTEH 
TWC-  F IGLGP 
TWC - FI  SLGp 
RWC-  FI STGR 
TWC- F ISTGR 
TWC - F ISTGP 
TWC-  FI STGP 
VVCMIE  -WPE 
TLC-  FVQWPE 
YVC-  FDQFPS 
ISC-AP-YPH 
TAC - I P- YPQ 
KTC-  ML-NAT 
TRC-  FEHYEK 
TRC-  FEHYEK 
VLCGVD-YSH 
PVC - YEVLGN 
TYCTFN - FAS  
TACVIS  - YPS  
TVCAFH-YES 
(212) CAFS  LAYAS LM - ALLVTS I FFCNGSVTL  - S L 
(182) AAFS  LAYAGLV - ALLVAAI  FLCNGSVTL  - S L 
(196) I GFSVLYSS LM - ALLVLATVVCNLGAMY - NL  
( 194 ) TAYLQLYATLL-  LLL IVSVLACNFSVI  L- NL  
(182) AAYS YMYAGFS - S FL I  LATVLCN - VLVCGAL 
(207) AAFSYMYAGFS-SFL ILATVLCN-VLVCGAL 
(182) AAFS  YMYAG FS - S FLI  LATIrLCN - VLVCG~_L 
(192) ~'VFGLI FALLG - SASVGLS LLLNTVSVA - TL  
(192) VAFGLMFALLG - SVSVGLS LLLNTVSVA - TL  
(194) VAFGLLFSMLG-GLSVGLSFLLNTVSVA-  TL  
(199) ~RFYLLLFAFLG - LLALGI  S FVCNAI  TGI  - S L 
(199) RFYLLF  FS FLG - LLALGVS FS CNAVTGV - TL  
(199) RFYLLFFSS LG - LLALGI  S FS CNAVTGV - TL  
(201) ALLAGL FAS LG - LVALLAALVC~/TLSGL - AL  
(203) ALLAGLFAGLG-LAALLAALVCNTLSGL-AL  
(205) L FFASAFAFLG - LLALTVTFS CN - LAT I  KAL  
(224) L FFASTFAFLG - LLALA I  TFACN - LAT I  KAL  
(204) VA~ASAFAC LG - LLALWTFACN - LAT I  KAL  
(204) VAFASAFAC LG - LLALVVTFACN - LAT I  KAL  
(194) KVYHI  CVTVL I  YFLPLLV IGYAYTVVGI  - TL  
(244) FTYHI  IV I  I LVYC FPLL I  MGI  TYT IVGI  - TL  
(209) LSYTTLLLVLQYFGPLCF I  FI  CYFK IY I  - RL  
(208) K IHSMASFLVFYVI  PLS  I ISVYYYF IAK  - NL  
(209) K IHSVL I  FLVYFL IPLA I  IS I  YYYHIAK-  TL  
(252) DVKDWWLFG FYFCMPLVCTAI  FYTLMTC EML 
(184) VL I  IH I  C IVLGFF IVFLL ILFCN - LV I  I HTL  
( 184 ) VL I IH I  F IVFSFFLVFL I  I LFCN-  LV I IRTL  
(200) RAVAIVRLVLG FLWPLLTLT I  CYTF I  LLRTW 
(200) MVLR I LPHTFGF I  VPL  VMLFCYGFTLR - TL  
(199) TARGI  I RFV IGFS  LPMS I VA I  CYGL IAAKI  H 
(195) V FTSTMLLNVVG FL  LPLSV I TFC  - TMQI  MQVL 
(193) I GLG LTKNT LGFLFPFL I  I LTSYTL  IW - KAL  
(304) LLAFRFNAI~NP I LD  pW - VF I  LFRKAVFQR - L 
(275) LLAFRFY~PI  LDPW - VF I  L FRKAVFQR - L 
(302) LQALRFLSVIS  IVDPW q I FI I FRTSVFRM-  L 
(298) LQALRFLS INS I IDPW q VFA I  LRPPVLRL  - M 
( 312 ) LQAI  R IASVNPILDPW-  IY I  LLRKTVLSKAI  
(340) LQAI  R IASVNP I LD  PW - I y I  LLRKTVLS KAI  
(315) LQAI  R IASVNPI  LD PW - I y I  LLRKTVLS KA I  
(288) LI  YLRVATWNQI  LDPW - VY I  L FRRSVLRR - L 
(288) L I  YLRVATWNQ I LDPW - VY I  LFRRSVLRR - L 
(291) L I  YLRVATWNQ I LDPW - VY I  L FRRAVLRR - L 
(287) LFTLRMATWNQILDPW-VY ILLRKAVLPM-  L 
(287) LFALRMATWNQILDPW-VY ILLRKAVLRN-  L 
(287) LF I~LRMATWNQ I LD PW - VY I  LLRKAVLRN - L 
(333) FLAVRLASWNQI  LD PW - VY I  LLRQAVLRQ - L 
(337) FLAVRLASWNQI  LD PW - VY I  LLRQAMLRQ - L 
(306) LI  AVRLAS LNQI  LDPW - VYLLLRKI  LLRK - F 
(325) L IAVRLASI /qQ I LDPW - VYLLLRKI  LLRK - F 
(305) LI  AVRLAS LNQ I LDPW - VYLLLRKI  LLRK - F 
(305) L IAVRLASLNQILDPW-VYLLLRKILLRK-  F 
(290) IMWLAMSS - TM- YNP I  - I YCCI//DR - FRLGF 
(340) SFWLAMSS - TM- YNP I  - I YCCLNKR-  FRAGF 
(306) HL-  TAMI  S - TC  -VNPI  - FYGFLNKN - FQRDL 
( 308 ) RL- LAFTN - SC -VNPFALY  - LLSKS - FRKQF 
( 309 ) RV-  LSFGN - SC -VNPFALY  - LLSES-  FRRHF 
( 353 ) G INLATMN - SC  - INP IALY  - FVSKK-  FKNCF 
(278) TLCL  - LST  - NCVLDPV - I YCFLTKK-  FRKHL 
( 278 ) TLCL-  LST  - IqCVLDPV - IYCFLTKK - FRKHL 
(285) CVS FAY IN  - CC - INP I  - I YVVAGQG-  FQGRL 
( 290) TE ILGFLH-  SC - LNP I  - I YAF IGQN-  FRHGF 
( 287 ) TSSLAFFN-  SC -LNPM-  LYVFVGQD-  FRERL  
( 290 ) AS  FMAYSN - SC - LNPL-  VYV IVGKR - FRKKS 
(287) T IC IAYFN-NC-LNPL-  FYGFLGKK-  FKRYF  
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Fig. 2. A phylogenetic ree of the receptors for PGs, TXA, LXA, PAF 
and peptides. A number neighboring a branch or indicated by an arrow 
in the tree shows the reliability of the branch, that is, the count of 
success of the branch during one thousand iterations of bootstrap 
resampling and tree reconstruction. A branch with a number greater 
than or equal to nine-hundreds was regarded to be statistically signifi- 
cant. 
The cluster consisting of peptide receptors included PAF and 
LXA receptors. The cluster was further divided into two sub- 
clusters, CL-4 and CL-5, at the node (b). CL-4 consisted of the 
receptors of neuropeptides and endothelin. The CL-5 included 
PAF receptors and a LXA receptor besides other peptide recep- 
tors. However, the origins of the two receptors for the lipid- 
derived ligands were different from each other. As shown in the 
tree, PAF receptors diverged at the early stage. Contrary to 
that, LXA receptor diverged more recently. Thus, it is sug- 
gested that the receptors for lipid-derived ligands have diverged 
from peptide receptors at least wice. In addition, the tree sug- 
gested that the origin oflipoxygenase pathway is different from 
that of cyclooxygenase pathway, that is, the two pathways have 
independently appeared and been integrated into the ara- 
chidonic acid cascade. 
The outline on the evolutionary history of the arachidonic 
acid cascade was discussed with limited number of available 
sequences. Several problems has remained unknown. For ex- 
ample, the receptors involved in the lipoxygenase pathway may 
have diverged from an ancestral peptide receptor, although 
only LXA receptor has been sequenced in the receptors in- 
volved in the pathway. Further accumulation f the sequences 
for the receptors would ascertain the evolutionary history in- 
fered here and reveal more details for the evolution of the 
arachidonic acid cascade. 
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